Uticaj galektina-3 na remodelovanje miokarda i rani klinički ishod kod pacijenata sa akutnim infarktom miokarda

Our study investigated association between galectin-3 levels and adverse left ventricular remodelling at six months. Eighty-six patients following first AMI and stable angina (control group) were enrolled in this study and blood samples collected on day 1 from the femoral vein and artery, the right atrium near the coronary sinus and the aortic root; on day 5 from cubital vein and radial artery; on day 30 from the cubital vein. Patients with LVESV ≥ 20% at six months, were included in the LVR group. In patients with acute myocardial infarction, on day 1, Galectin-3 plasma levels in the femoral vein (10.34 ng/ml ± 3.81 vs 8.22 ng/ml ± 2.34, p=0.01), and coronary sinus (10.7 ng/ml ± 3.97 vs 8.41 ng/ml ± 2.56, p=0.007) were higher in the LVR group. Positive correlations between galectin-3 levels from aortic root and coronary sinus, aortic root and femoral vein, and coronary sinus and femoral vein were observed in both groups. On day 30, galectin-3 concentration in the cubital vein was an independent risk factor of LVR six months post-AMI, demonstrating 1.5-fold increased risk. Day-30 galectin-3 showed positive correlations with echocardiography parameters indicative of diastolic and systolic dysfunction. On day one galectin-3 levels in aortic root are significantly higher in patients with fatal outcome six months later. Determining galectin-3 plasma concentration on day 30 following AMI could have beneficial prognostic value in predicting LVR.